The vast majority of patients with differentiated thyroid cancer (DTC) are treated successfully
with surgery and radioactive iodine ablation, yet the treatment of advanced cases is …

Thyroid cancer (TC) is the most common endocrine malignancy with steadily increasing
incidence over the past few decades. Although standard strategies for the management of …

Differentiated thyroid cancer (DTC) is the most common endocrinological malignancy. There
are several histological variants such as papillary and follicular thyroid carcinoma. Many …

Differentiated thyroid carcinomas (DTCs) that arise from follicular cells account> 90% of
thyroid cancer (TC)[papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 10%] …

Differentiated thyroid cancer (DTC) is the most common endocrine malignancy. The
standard treatment for DTC includes surgery, radioiodine ablation, and thyroid hormone …

Derived from follicular epithelial cells, differentiated thyroid cancer (DTC) accounts for the
majority of thyroid malignancies. The threefold increase in DTC incidence over the last three …

The spectrum of thyroid cancers ranges from one of the most indolent to one of the most
aggressive solid tumors identified. Conventional therapies for thyroid cancers are based on …

Differentiated thyroid carcinoma (DTC) accounts for more than 90% of new thyroid cancer
diagnoses, and includes papillary, follicular and Hürthle cell carcinoma. The prognosis for …

Thyroid cancer comprises different clinical and histological entities. Whereas differentiated
(DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary …

The histology and clinical behavior of thyroid cancer are highly diverse. Although most are
indolent tumors with a very favorable outcome with the current standard of care therapy, a …